Results 111 to 120 of about 1,664,116 (319)

High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus

open access: yesVascular Health and Risk Management, 2019
I Made Junior Rina Artha,1 Agha Bhargah,1,2 Nyoman Khrisna Dharmawan,2 Utami Wijayaswari Pande,2 Komang Agus Triyana,2 Pande Agung Mahariski,2 Jessica Yuwono,2 Varennia Bhargah,2 I Putu Yuda Prabawa,3 Ida Bagus Amertha Putra Manuaba,4,5 I Ketut ...
Artha IMJR   +10 more
doaj  

SNUPN‐Related Muscular Dystrophy: Novel Phenotypic, Pathological and Functional Protein Insights

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SNUPN‐related muscular dystrophy or LGMDR29 is a new entity that covers from a congenital or childhood onset pure muscular dystrophy to more complex phenotypes combining neurodevelopmental features, cataracts, or spinocerebellar ataxia. So far, 12 different variants have been described.
Nuria Muelas   +18 more
wiley   +1 more source

Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction

open access: yesVascular Health and Risk Management, 2008
Lena Björck1, Catharina Welin2, Annika Rosengren11Department of medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden; 2Institute of Health and Care Sciences, the Sahlgrenska Academy at Göteborg University, Göteborg ...
Lena Björck   +2 more
doaj  

Is a Single Lipoprotein(a) Measurement Once in a Lifetime Sufficient? The Results from the STAR-Lp(a) Study

open access: yesMedical Sciences
Background: Guidelines suggest that a single lifetime measurement of lipoproteina(a) [Lp(a)] is sufficient for most patients as its levels are largely genetically determined and do not significantly change over time.
Monika Burzyńska   +3 more
doaj   +1 more source

Impact of APOE ε4 Genotype Load on Cognitive Function and Lipid Metabolism in Patients With Cerebral Small Vessel Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin   +6 more
wiley   +1 more source

A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution

open access: yesInternational Journal of Nanomedicine, 2012
Mingshu Ma,1 Yanli Hao,1 Nan Liu,1 Zhe Yin,1 Lan Wang,1 Xingjie Liang,2 Xiaoning Zhang11Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, China; 2National Center for Nanoscience and Technology ...
Ma M   +6 more
doaj  

Lipoprotein (a) Screening, and What's Next?

open access: yesJournal of Cardiovascular Emergencies
Lipoprotein (a) (Lp(a)) is a low-density lipoprotein (LDL) in which the apolipoprotein B100 molecule is bound to a highly polymorphic, plasminogen-like apolipoprotein (a).
Pasławska Anna   +2 more
doaj   +1 more source

Influence of the dietary polyunsaturation level on chicken meat quality: lipid oxidation

open access: hybrid, 2005
L. Cortinas   +5 more
openalex   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy